IL17A and psoriasis: In mice with overexpressed IL-36α in keratinocytes but an otherwise normal phenotype, 12-O-tetradecanoylphorbol-13-acetate (TPA) treatment results in a considerable increase in skin inflammation that morphologically mimics psoriasis, as well as a significant rise in IL-17A, IL-22, and IL-23.